Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 784Lung Neoplasms 346Small Cell Lung Carcinoma 146Adenocarcinoma of Lung 71Neoplasms 44Neoplasm Metastasis 34Adenocarcinoma, Bronchiolo-Alveolar 30Colorectal Neoplasms 25Ovarian Neoplasms 24Carcinoma 24Lung Diseases 18Parkinson Disease 4, Autosomal Dominant Lewy Body 17Breast Neoplasms 17Mesothelioma 16Thoracic Neoplasms 15Respiratory Tract Neoplasms 15Mesothelioma, Malignant 15Pancreatic Neoplasms 13NSCLC 13Endometrial Neoplasms 13Squamous Cell Carcinoma of Head and Neck 12Carcinoma, Bronchogenic 12Adenocarcinoma 12Melanoma 11Triple Negative Breast Neoplasms 10Stomach Neoplasms 10Brain Neoplasms 10Respiratory Tract Diseases 9Head and Neck Neoplasms 9Carcinoma, Squamous Cell 9

Interventions

Platinum Compounds 2Paclitaxel 2Cisplatin 2Carboplatin 2sintilimab 1osimertinib 1cemiplimab 1Surgical Procedures, Operative 1Pemetrexed 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Resectable Non-small Cell Lung Cancer × Carboplatin × Thoracic × Clear all
NCT06161441 2026-05-28

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
195 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

NCT05247684 2026-03-05

AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

Akeso

Phase 2 Active not recruiting
90 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡